SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 8.93% Stake in Moleculin Biotech

Armistice Capital, LLC and its managing member Steven Boyd have reported a beneficial ownership of 8.93% in Moleculin Biotech, Inc., holding 1,250,000 shares of common stock as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Moleculin Biotech, Inc.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 1,250,000 shares of Moleculin Biotech, Inc. Common Stock.
• This ownership represents 8.93% of the issuer's outstanding Common Stock.
• Armistice Capital, LLC, acting as the investment manager for Armistice Capital Master Fund Ltd., and Steven Boyd, as its managing member, exercise shared voting and dispositive power over these shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Moleculin Biotech, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance metrics that would indicate a positive or negative sentiment. It is neutral.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a standard disclosure of beneficial ownership by an institutional investor in a publicly traded company within the biotechnology sector. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.

Key Dates

Keywords

Moleculin Biotech, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional ownership, biotech